Meridian Bioscience Inc. (VIVO) Position Cut by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL cut its position in shares of Meridian Bioscience Inc. (NASDAQ:VIVO) by 35.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 32,223 shares of the company’s stock after selling 17,645 shares during the period. Tudor Investment Corp ET AL owned 0.08% of Meridian Bioscience worth $508,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. UBS Asset Management Americas Inc. boosted its holdings in Meridian Bioscience by 0.7% during the second quarter. UBS Asset Management Americas Inc. now owns 13,091 shares of the company’s stock worth $206,000 after buying an additional 92 shares in the last quarter. Arizona State Retirement System boosted its holdings in Meridian Bioscience by 0.5% during the second quarter. Arizona State Retirement System now owns 22,041 shares of the company’s stock worth $347,000 after buying an additional 100 shares in the last quarter. Texas Permanent School Fund boosted its holdings in Meridian Bioscience by 0.8% during the second quarter. Texas Permanent School Fund now owns 30,813 shares of the company’s stock worth $485,000 after buying an additional 258 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its holdings in Meridian Bioscience by 3.9% during the second quarter. Municipal Employees Retirement System of Michigan now owns 9,950 shares of the company’s stock worth $157,000 after buying an additional 370 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its holdings in Meridian Bioscience by 0.5% during the second quarter. PNC Financial Services Group Inc. now owns 103,882 shares of the company’s stock worth $1,635,000 after buying an additional 485 shares in the last quarter. 87.30% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Meridian Bioscience Inc. (NASDAQ:VIVO) opened at 14.70 on Wednesday. The firm’s 50 day moving average is $14.11 and its 200-day moving average is $14.32. The firm has a market capitalization of $620.38 million, a PE ratio of 29.40 and a beta of 0.84. Meridian Bioscience Inc. has a 12 month low of $10.75 and a 12 month high of $19.40.

Meridian Bioscience (NASDAQ:VIVO) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.16 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.16. Meridian Bioscience had a net margin of 10.77% and a return on equity of 16.93%. The company had revenue of $50.14 million during the quarter, compared to the consensus estimate of $49.13 million. During the same quarter in the prior year, the company posted $0.21 EPS. The company’s quarterly revenue was down 1.0% compared to the same quarter last year. On average, analysts expect that Meridian Bioscience Inc. will post $0.67 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://stocknewstimes.com/2017/10/11/meridian-bioscience-inc-vivo-position-cut-by-tudor-investment-corp-et-al.html.

Several research firms have issued reports on VIVO. BidaskClub downgraded shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Thursday, July 6th. Zacks Investment Research raised shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a report on Thursday, October 5th. Two research analysts have rated the stock with a sell rating and five have assigned a hold rating to the company. Meridian Bioscience presently has a consensus rating of “Hold” and an average target price of $14.33.

In related news, Chairman John A. Kraeutler acquired 7,000 shares of the company’s stock in a transaction dated Thursday, August 24th. The stock was bought at an average price of $13.67 per share, with a total value of $95,690.00. Following the purchase, the chairman now directly owns 345,230 shares in the company, valued at approximately $4,719,294.10. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.30% of the company’s stock.

About Meridian Bioscience

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience Inc. (NASDAQ:VIVO).

Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply